NovoCure stock gets Japan approval for Optune Pax

Published on 10/04/2026 at 21:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

NovoCure stock follows Japan approval for Optune Pax on October 1, while second-quarter revenue rose 15.6 percent to USD 183.58 million. Analysts rate NVCR Hold.

NVCR, JE00BYSS4X48, Illustration mit AI erstellt.

NovoCure stock (ISIN JE00BYSS4X48) closed at USD 14.94 on Nasdaq on October 2, 2026, down 6.16 percent from USD 15.92. The company then secured a regulatory milestone in Japan as Business Wire reported on October 1, 2026, that the country's health ministry approved Optune Pax for adults with unresectable locally advanced pancreatic cancer.

Japan approval expands the product case

The approval covers Optune Pax in combination with gemcitabine and nab-paclitaxel. Novocure said the decision was based on the Phase 3 PANOVA-3 trial, which met its primary endpoint with a statistically significant improvement in median overall survival.

The safety profile remains a central commercial consideration. In the trial, device-related skin adverse events occurred in 76.3 percent of treated participants, while 21 participants, or 7.7 percent, experienced a Grade 3 or higher event, according to Business Wire.

Revenue growth meets an earnings test

The latest reported quarter gives the approval a financial baseline. In Q2 2026, revenue reached USD 183.58 million, up 15.6 percent from the year-earlier period, while adjusted loss per share was USD 0.13 compared with a consensus loss of USD 0.33, according to MarketBeat. The USD 0.20 improvement against consensus matters because the company remains loss-making, with a reported net margin of negative 21.25 percent.

The next test is already scheduled. Novocure will report Q3 2026 results on October 29, 2026, before U.S. markets open, with its conference call set for 8:00 a.m. EDT, according to Novocure.

Analysts keep a Hold consensus

Market expectations remain measured despite the product milestone. Seven covering firms assign NovoCure an average Hold rating, with two Buys, four Holds and one Sell; the average 12-month target is USD 21.20, according to MarketBeat. That target stands 41.90 percent above the October 2 closing price of USD 14.94, putting execution and commercialization ahead of rating optimism.

NVCR remains below its yearly high

NovoCure closed at USD 14.94 on Nasdaq on October 2, 2026, within a 52-week range of USD 9.82 to USD 21.45 and 30.35 percent below the high. The market capitalization was USD 1.7 billion, with volume of 1,695,114 shares.